List of works - Luis Almeida

A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

scientific article published on December 2010

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I.

scientific article

Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.

scientific article

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease

scientific article

Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor

scientific article published in May 2010

Disability and its clinical correlates in pulmonary hypertension measured through the World Health Organization Disability Assessment Schedule 2.0: a prospective, observational study

scientific article published on 30 May 2019

Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease

article

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

scientific article published on 18 June 2010

Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women

scientific article published on 6 April 2013

Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.

scientific article published on 4 June 2009

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

scientific article published on January 2010

Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093).

scientific article published in January 2005

Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker

scientific article published in July 2007

Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

scientific article

Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

scientific article

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

scientific article published in November 2009

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies

scientific article

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

scientific article published on 21 February 2009

Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures

scientific article published on 21 February 2007

Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations

scientific article published in January 2005

Eslicarbazepine acetate (BIA 2-093).

scientific article

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

scientific article published on 17 March 2010

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.

scientific article

Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

scientific article published on 01 February 2012

Hesperetin-etoposide combinations induce cytotoxicity in U2OS cells: Implications on therapeutic developments for osteosarcoma

scientific article published on 28 December 2016

Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation

scientific article published on 21 June 2006

Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.

scientific article published on June 2014

Intramuscular Etofenamate versus Diclofenac in the Relief of Renal Colic : A Randomised, Single-Blind, Comparative Study.

scientific article

Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy

scientific article published on October 2010

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study

scientific article published on 4 August 2012

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects

scientific article (publication date: 21 October 2013)

Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects.

scientific article published in December 2003

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

scientific article published in May 2009

Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

scientific article published on 28 December 2009

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects

scientific article published in June 2010

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

scientific article published on 27 September 2003

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa

scientific article published in January 2004

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects

scientific article published in October 2009

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subject

scientific article

Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans

scientific article published in January 2003

Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

scientific article

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study

scientific article published in June 2011

Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures

article

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

scientific article published on 21 December 2007

Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects

scientific article published in October 2009

Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans

scientific article published on August 2010

Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.

scientific article published on January 2012

Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy

scientific article published on 28 May 2008

Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

scientific article published in February 2013

Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire

scientific article published on 26 July 2016

Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans

scientific article published in January 2003

Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans

scientific article

Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5-453), a New Dopamine β-Hydroxylase Inhibitor, in Healthy Subjects

scientific article published on 01 February 2012

Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects

scientific article published in September 2005

Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

scientific article

Sulforaphane induces oxidative stress and death by p53-independent mechanism: implication of impaired glutathione recycling

scientific article

The Use of Procalcitonin (PCT) for Diagnosis of Sepsis in Burn Patients: A Meta-Analysis

scientific article

Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events

scientific article published in June 2008

Why healthy subjects volunteer for phase I studies and how they perceive their participation?

scientific article published on 20 September 2007

List of works by Luis Almeida

A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I.

Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease

Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor

Disability and its clinical correlates in pulmonary hypertension measured through the World Health Organization Disability Assessment Schedule 2.0: a prospective, observational study

Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women

Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093).

Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker

Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures

Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations

Eslicarbazepine acetate (BIA 2-093).

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.

Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

Hesperetin-etoposide combinations induce cytotoxicity in U2OS cells: Implications on therapeutic developments for osteosarcoma

Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation

Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.

Intramuscular Etofenamate versus Diclofenac in the Relief of Renal Colic : A Randomised, Single-Blind, Comparative Study.

Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects

Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects.

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subject

Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans

Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study

Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects

Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans

Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.

Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy

Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire

Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans

Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans

Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5-453), a New Dopamine β-Hydroxylase Inhibitor, in Healthy Subjects

Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects

Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

Sulforaphane induces oxidative stress and death by p53-independent mechanism: implication of impaired glutathione recycling

The Use of Procalcitonin (PCT) for Diagnosis of Sepsis in Burn Patients: A Meta-Analysis

Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events

Why healthy subjects volunteer for phase I studies and how they perceive their participation?